Investigating significant health trends in growth hormone treatments registry: rationale, aims and design of a nationwide prospective registry (study protocol)
Somatropin treatment is indicated in a variety of disorders including growth hormone (GH) deficiency, Prader –Willi and Turner syndrome, chronic renal insufficiency and others. To date, almost all studies have ... (Source: Orphanet Journal of Rare Diseases)
Source: Orphanet Journal of Rare Diseases - May 10, 2023 Category: Internal Medicine Authors: Dirk Schnabel, Ilonka Kreitschmann-Andermahr, Christian J. Strasburger, David Pittrow, Christine Pausch and Joachim Woelfle Tags: Research Source Type: research
Early GH Treatment is Effective and Well Tolerated in Children with Turner Syndrome: NordiNet ® IOS and ANSWER Program
CONCLUSIONS: Growth hormone-treated participants with TS responded well, without new safety concerns. Our real-world data are in agreement with previous studies.CLINICAL TRIAL REGISTRATION: NordiNet® IOS (ClinicalTrials.gov, NCT00960128); the ANSWER Program (ClinicalTrials.gov, NCT01009905).PMID:36947589 | DOI:10.1210/clinem/dgad159 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - March 22, 2023 Category: Endocrinology Authors: Philippe Backeljauw Joanne C Blair Jean-Marc Ferran Nicky Kelepouris Bradley S Miller Alberto Pietropoli Michel Polak Lars S ävendahl Franciska Verlinde Tilman R Rohrer Source Type: research
The influence of growth hormone on pediatric body composition: A systematic review
ConclusionDespite study limitations (i.e., potential effects of diet and physical activity were not considered), we concluded that a periodic body composition assessment is required to ensure that a satisfactory body composition is achieved during GH replacement therapy in children with GHD. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - February 9, 2023 Category: Endocrinology Source Type: research
EE589 Cost-Effectiveness of Once-Daily Somatropin From Sandoz Versus Once-Weekly Somatrogon for the Treatment of Growth Hormone Deficiency in Children and Adolescents
Recent approval of once-weekly somatrogon for Growth Hormone Deficiency (GHD) treatment in paediatric patients has provided an opportunity to assess its economic impact compared to already available once-daily somatropin. This research aims to determine the cost-effectiveness of weekly somatrogon compared to daily somatropin from Sandoz for the treatment of paediatric GHD, from the perspective of payers in Germany and the United Kingdom (UK). (Source: Value in Health)
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: A Mehl, A Goh, S Gupta Source Type: research
EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency
Pediatric growth hormone deficiency (pGHD) is defined as growth failure associated with inadequate growth hormone (GH) production. Daily injections of recombinant human GH (dGH) [somatropin] is the current standard of care, which has been shown to be safe and effective, however with suboptimal adherence, leading to reduced effectiveness. Somatrogon, a once-weekly injectable long-acting human GH, has demonstrated clinical non-inferiority and significantly lower life interference vs. somatropin. This work aimed to evaluate cost-effectiveness and cost-utility of somatrogon vs dGHs across 5 countries (United States, Canada, Sp...
Source: Value in Health - December 1, 2022 Category: International Medicine & Public Health Authors: S Rivolo, J Loftus, B Peter, M Fahey, S Toghanian, C Peral, C Khanji, M Stewart, T Kongnakorn Source Type: research
Somatrogon in paediatric growth hormone deficiency: a profile of its use in the EU
AbstractSomatrogon (NGENLA®), a modified long-acting form of recombinant human growth hormone (rhGH), is a valuable new option for the treatment of paediatric patients aged ≥ 3 years with growth disturbance due to insufficient GH secretion in the EU, and offers the convenience of once-weekly administration. In a phase 3 randomized trial, once-weekly somatrogon was non-inferior to once-daily somatropin (rhGH; standard therapy) in increasing height velocity in paedia tric patients with GH deficiency (GHD). Once-weekly somatrogon was associated with a lower treatment burden than once-daily somatropin in another phase 3 r...
Source: Drugs and Therapy Perspectives - November 18, 2022 Category: Drugs & Pharmacology Source Type: research
Persistence with daily growth hormone among children and adolescents with growth hormone deficiency in the UK
ConclusionsDespite high early persistence with somatropin, a high percentage of children with GHD were increasingly non-persistent over time. More than 1 in 4 were non-persistent at 12 months and more than 1 in 2 were non-persistent at 48 months of follow-up. These results suggest that strategies to support improved medication-taking behavior among children with GHD in the UK are warranted. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - November 3, 2022 Category: Endocrinology Source Type: research
Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
CONCLUSION: As most adolescents had vitamin D insufficiency, low calcium intake, and physical inactivity, calcium, and cholecalciferol supplementation and lifestyle changes should be encouraged. The Brazilian Afro-descendant may be a vulnerable group for low bone mass, requiring special strategies to increase bone accrual and body weight. More studies are necessary to compare ethnic differences in this population.PMID:36155741 | DOI:10.1016/j.jped.2022.08.001 (Source: Jornal de Pediatria)
Source: Jornal de Pediatria - September 26, 2022 Category: Pediatrics Authors: Valesca M Kuba Antonia B S Castro Cl áudio Leone Durval Damiani Source Type: research
Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
CONCLUSION: As most adolescents had vitamin D insufficiency, low calcium intake, and physical inactivity, calcium, and cholecalciferol supplementation and lifestyle changes should be encouraged. The Brazilian Afro-descendant may be a vulnerable group for low bone mass, requiring special strategies to increase bone accrual and body weight. More studies are necessary to compare ethnic differences in this population.PMID:36155741 | DOI:10.1016/j.jped.2022.08.001 (Source: Jornal de Pediatria)
Source: Jornal de Pediatria - September 26, 2022 Category: Pediatrics Authors: Valesca M Kuba Antonia B S Castro Cl áudio Leone Durval Damiani Source Type: research
Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
CONCLUSION: As most adolescents had vitamin D insufficiency, low calcium intake, and physical inactivity, calcium, and cholecalciferol supplementation and lifestyle changes should be encouraged. The Brazilian Afro-descendant may be a vulnerable group for low bone mass, requiring special strategies to increase bone accrual and body weight. More studies are necessary to compare ethnic differences in this population.PMID:36155741 | DOI:10.1016/j.jped.2022.08.001 (Source: Jornal de Pediatria)
Source: Jornal de Pediatria - September 26, 2022 Category: Pediatrics Authors: Valesca M Kuba Antonia B S Castro Cl áudio Leone Durval Damiani Source Type: research
Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
CONCLUSION: As most adolescents had vitamin D insufficiency, low calcium intake, and physical inactivity, calcium, and cholecalciferol supplementation and lifestyle changes should be encouraged. The Brazilian Afro-descendant may be a vulnerable group for low bone mass, requiring special strategies to increase bone accrual and body weight. More studies are necessary to compare ethnic differences in this population.PMID:36155741 | DOI:10.1016/j.jped.2022.08.001 (Source: Jornal de Pediatria)
Source: Jornal de Pediatria - September 26, 2022 Category: Pediatrics Authors: Valesca M Kuba Antonia B S Castro Cl áudio Leone Durval Damiani Source Type: research
Osteometabolic profile and bone mass in the transition phase: ethnic differences in Brazilians treated with somatropin during childhood
CONCLUSION: As most adolescents had vitamin D insufficiency, low calcium intake, and physical inactivity, calcium, and cholecalciferol supplementation and lifestyle changes should be encouraged. The Brazilian Afro-descendant may be a vulnerable group for low bone mass, requiring special strategies to increase bone accrual and body weight. More studies are necessary to compare ethnic differences in this population.PMID:36155741 | DOI:10.1016/j.jped.2022.08.001 (Source: Jornal de Pediatria)
Source: Jornal de Pediatria - September 26, 2022 Category: Pediatrics Authors: Valesca M Kuba Antonia B S Castro Cl áudio Leone Durval Damiani Source Type: research
